Galapagos N.V. (GLPG) - Total Assets
Based on the latest financial reports, Galapagos N.V. (GLPG) holds total assets worth €3.37 Billion EUR (≈ $3.94 Billion USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore debt repayment capacity of Galapagos N.V. to assess how comfortably operating cash covers total debt obligations.
Galapagos N.V. - Total Assets Trend (2004–2025)
This chart illustrates how Galapagos N.V.'s total assets have evolved over time, based on quarterly financial data. See Galapagos N.V. (GLPG) shareholders funds for net asset value and shareholders' equity analysis.
Galapagos N.V. - Asset Composition Analysis
Current Asset Composition (December 2025)
Galapagos N.V.'s total assets of €3.37 Billion consist of 90.4% current assets and 9.6% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 2.6% |
| Accounts Receivable | €51.91 Million | 1.5% |
| Inventory | €22.49 Million | 0.7% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €848.00K | 0.0% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2004–2025)
This chart illustrates how Galapagos N.V.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market value of Galapagos N.V..
Key Asset Composition Facts
- Current vs. Non-Current Assets: Galapagos N.V.'s current assets represent 90.4% of total assets in 2025, an increase from 80.3% in 2004.
- Cash Position: Cash and equivalents constituted 2.6% of total assets in 2025, down from 65.8% in 2004.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 2.0% in 2004.
- Asset Diversification: The largest asset category is accounts receivable at 1.5% of total assets.
Galapagos N.V. Competitors by Total Assets
Key competitors of Galapagos N.V. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $2.01 Billion |
|
ALTEOGEN Inc
KQ:196170
|
Korea | ₩729.47 Billion |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE
|
USA | $1.29 Billion |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX
|
USA | $440.10 Million |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Blue Jet Healthcare Limited
NSE:BLUEJET
|
India | Rs16.41 Billion |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
|
R&G PharmaStudies Co. Ltd. A
SHE:301333
|
China | CN¥2.40 Billion |
Galapagos N.V. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 30.48 | 7.95 | 8.89 |
| Quick Ratio | 30.30 | 7.86 | 8.89 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €2.96 Billion | €3.04 Billion | €4.55 Billion |
Galapagos N.V. - Advanced Valuation Insights
This section examines the relationship between Galapagos N.V.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.49 |
| Latest Market Cap to Assets Ratio | 0.46 |
| Asset Growth Rate (YoY) | -17.6% |
| Total Assets | €3.41 Billion |
| Market Capitalization | $1.55 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Galapagos N.V.'s assets below their book value (0.46x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Galapagos N.V.'s assets decreased by 17.6% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Galapagos N.V. (2004–2025)
The table below shows the annual total assets of Galapagos N.V. from 2004 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €3.41 Billion ≈ $3.98 Billion |
-17.63% |
| 2024-12-31 | €4.14 Billion ≈ $4.84 Billion |
-5.09% |
| 2023-12-31 | €4.36 Billion ≈ $5.09 Billion |
-7.96% |
| 2022-12-31 | €4.73 Billion ≈ $5.53 Billion |
-8.83% |
| 2021-12-31 | €5.19 Billion ≈ $6.07 Billion |
-9.17% |
| 2020-12-31 | €5.72 Billion ≈ $6.68 Billion |
-5.78% |
| 2019-12-31 | €6.07 Billion ≈ $7.09 Billion |
+321.58% |
| 2018-12-31 | €1.44 Billion ≈ $1.68 Billion |
+11.91% |
| 2017-12-31 | €1.29 Billion ≈ $1.50 Billion |
+18.73% |
| 2016-12-31 | €1.08 Billion ≈ $1.27 Billion |
+144.81% |
| 2015-12-31 | €442.51 Million ≈ $517.35 Million |
+63.61% |
| 2014-12-31 | €270.47 Million ≈ $316.20 Million |
-5.88% |
| 2013-12-31 | €287.37 Million ≈ $335.97 Million |
+22.12% |
| 2012-12-31 | €235.33 Million ≈ $275.12 Million |
+46.12% |
| 2011-12-31 | €161.06 Million ≈ $188.29 Million |
-16.97% |
| 2010-12-31 | €193.96 Million ≈ $226.76 Million |
+34.97% |
| 2009-12-31 | €143.71 Million ≈ $168.01 Million |
+20.94% |
| 2008-12-31 | €118.82 Million ≈ $138.92 Million |
-20.10% |
| 2007-12-31 | €148.72 Million ≈ $173.87 Million |
-11.29% |
| 2006-12-31 | €167.65 Million ≈ $196.00 Million |
+105.54% |
| 2005-12-31 | €81.56 Million ≈ $95.36 Million |
+422.40% |
| 2004-12-31 | €15.61 Million ≈ $18.25 Million |
-- |
About Galapagos N.V.
Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that is in phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory no… Read more